AdvanCell

Venture-backed company · Stage unknown
Rounds on record
1
Latest round
Jun 30, 2026
Form D equity offering
Latest round size
$218M
Form D industry: Biotechnology
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

6 additional officers and directors

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. $218M
    sold on Form D

    Filed a Form D on 30 Jun 2026: $218M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.

    A company that just raised has fresh capital, a new board and new vendors to choose.

    FactSEC Form DFor Investors, lenders, service providersFinancing history →
  2. 1 investor
    named

    1 investor on record.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
  3. 9 directors
    board

    9 directors on record from Form D filings and board-seat attributions.

    The board is who decides on the next round and on a sale.

    FactSEC Form D related personsFor Investors, acquirersPeople →
Drawing the relationship network…
Facts
Year of incorporation
2026sec.gov
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
1
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
1
Financing history
1 round
  1. Jun 30, 2026
    Form D equity offering · $218M (form d sold) · 41 investors
    Fact Form D · “AdvanCell, Inc. filed Form D: $218,333,294 sold of $315,000,000, Biotechnology”
Investors on record
1 edge
Ownership and outcomes
none on record
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationships
none on record
No lender position matched to this company.
People
2 officers, 9 directors
Timeline
1 event
  1. Jul 16, 2026
    AdvanCell, Inc. filed Form D: $218,333,294 sold of $315,000,000, Biotechnology
    Form D filed Fact Form D
Evidence
18 observations
Every observation on this company
  • Entity type: Corporation Jul 16, 2026 Fact Form D
  • Form D industry group: Biotechnology Jul 16, 2026 Fact Form D
  • Amendment: false Jul 16, 2026 Fact Form D
  • Revenue range (Form D): Decline to Disclose Jul 16, 2026 Fact Form D
  • Incorporated: withinFiveYears Jul 16, 2026 Fact Form D
  • Jurisdiction: Delaware Jul 16, 2026 Fact Form D
  • Amount sold (Form D): $218M Jul 16, 2026 Fact Form D
  • Offering amount (Form D): $315M Jul 16, 2026 Fact Form D
  • Exemptions: 06b Jul 16, 2026 Fact Form D
  • First sale: 2026-06-30 Jul 16, 2026 Fact Form D
  • Investors (Form D): 41 Jul 16, 2026 Fact Form D
  • Minimum investment (Form D): 0 Jul 16, 2026 Fact Form D
  • Securities offered: equity Jul 16, 2026 Fact Form D
  • Office address: Jul 16, 2026 Fact Form D
  • Listed on portfolio page: Catalio Capital Management, LP Sep 30, 2026 Fact Firm website
  • Listed on portfolio page: Catalio Capital Management, LP Sep 16, 2026 Fact Firm website
  • Listed on portfolio page: Catalio Capital Management, LP Sep 15, 2026 Fact Firm website
  • Year of incorporation: 2026 Jul 16, 2026 Fact Form D

Relationships across DFX

on 1 other DFX graph
Across the graphs

AdvanCell is the same institution as 1 record in Private Equity.

Private Equity1

The joined record opens with the product, beside every other relationship on this page.

Checking your plan…

Record history

1 dated event on the change ledger, latest event first
  • Form D filed
    2026-07-16source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.